Formulary Search Results for: USTEKINUMAB
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use in accordance with the prescribing notes below.
Prescribing Notes:
Psoriasis in adults:
- The treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systematic therapies including ciclosporin, methotrexate and psoralen and UVA treatment (PUVA) is restricted to specialist use. Continued treatment should be restricted to patients who achieve a PASI 75% response within 16 weeks.
Psoriasis in adolescents:
- The treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies is restricted to specialist use. Continued treatment should be restricted to patients who achieve at least 75% improvement in their Psoriasis Area and Severity Index (PASI 75) within 16 weeks.
Ustekinumab should be prescribed by brand name. Wezenla® is the preferred biosimilar.
For use in psoriatic arthritis see section 10.1.3.
10.1.3 Drugs that suppress the rheumatic disease process - View Category
Restrictions:
The use as monotherapy or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug therapy has been inadequate, is restricted to specialist use in patients with active psoriatic arthritis who have failed on, or are unsuitable for, treatment with an anti-TNF drug.
Prescribing Notes:
Ustekinumab should be prescribed by brand name. Wezenla® is the preferred biosimilar.
For use in psoriasis, see section 13.5.3.